AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20681275
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (anti-platelet, blood lipid regulating, anti-ischemia) without SXBXP.
Trial: 20681275
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill (SXBXP)
Trial: 12455714
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (ACEI) for four weeks
Trial: 8530573
Drug: leuprolide depot
RxNorm normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leuprolide depot (3.75 mg/month) plus conjugated estrogen (0.625 mg/day) and medroxyprogesterone acetate (10 mg; days 1‐12)
Trial: 8530573
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (OCP) containing ethynodiol diacetate (1 mg) and ethinyl estradiol (35 micrograms)
Trial: 30037514
Drug: 30 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL/kg of intravenous Lactated Ringer's solution (LR)
Trial: 26690555
Drug: Acetaminophen (APAP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP; 1 g every 6 hours for seven days)
Trial: 24612987
Drug: Trimethoprim-sulfamethoxazole (160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160/800 mg daily)
Trial: 22065252
Drug: Modular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular treatment (62 youths)
Trial: 22065252
Drug: Standard manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard manual treatment (59 youths)
Trial: 16217327
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin B (5,000 IU diluted up to 20 ml)
Trial: 8018617
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml normal saline)
Trial: 11948071
Drug: Placebo-controlled study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-controlled study for treatment of asthma
Trial: 9585802
Drug: Eprosartan 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 350 mg
Trial: 9585802
Drug: Eprosartan 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 10 mg
Trial: 9585802
Drug: Eprosartan 30
RxNorm normalized name: eprosartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 30 mg
Trial: 9585802
Drug: Eprosartan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 50 mg
Trial: 9585802
Drug: Eprosartan 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 70 mg
Trial: 9597557
Drug: Eprosartan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 100 mg
Trial: 9597557
Drug: Eprosartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 200 mg
Trial: 7857995
Drug: Active experimental
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active experimental drug
Trial: 31941795
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 2,700 mg/d for adults; 30 mg/kg/d for pediatrics
Trial: 28662618
Drug: Face-to-face treatments
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face treatments (16 studies)
Trial: 28662618
Drug: Self-guided treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided treatments (11 studies)
Trial: 21645184
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch (9.5 mg/24 h)
Trial: 21312297
Drug: Rivastigmine capsules
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules (12 mg/day)
Trial: 19334486
Drug: ronkoleukine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ronkoleukine therapy (0.1 mg submucously and 0.4 mg intravenously, 3 times with 72 hour intervals)
Trial: 19334486
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy (proton pump inhibitor and two antibiotics: amoxicillin and clarithromycin)
Trial: 16686568
Drug: Mock Treatment
RxNorm normalized name: smocks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock Treatment (MT; 29.50 degrees C)
Trial: 10357114
Drug: Sodium aurothiomalate
RxNorm normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium aurothiomalate (gold therapy)
Trial: 7594922
Drug: Multidrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug therapy regimen including rifampin, isoniazid, clofazimine, and dapsone for the first 3 months followed by clofazimine and dapsone until 84 months.
Trial: 7395586
Drug: Assertiveness training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertiveness training (twice a week for one hour for 10 weeks)
Trial: 30604381
Drug: GM1 acupoint
RxNorm normalized name: Ganglioside GM1
DrugBank: Ganglioside GM1 (DB16948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM1 acupoint injection (group A)
Trial: 30604381
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (group B)
Trial: 27998971
Drug: S-288310 at
RxNorm normalized name: crospovidone (15 mpa.s at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-288310 at 1 mg
Trial: 27998971
Drug: S-288310 at
RxNorm normalized name: crospovidone (15 mpa.s at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-288310 at 2 mg
Trial: 25090414
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG), 10% Purified (Gamunex) administered monthly.
Trial: 25090414
Drug: 0.1% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% albumin solution (placebo) administered monthly.
Trial: 17240130
Drug: Wormwood (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wormwood (3 x 500 mg/day)
Trial: 15665022
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg three times daily for 6 months
Trial: 9658743
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc tolerance test
Trial: 9658743
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc dipicolinate tolerance test
Trial: 30898388
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen (IA) 1000 mg every 6 hours
Trial: 30898388
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen (IA)
Trial: 29145879
Drug: 2×10^6 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×10^6 per kilogram human umbilical-cord-derived MSCs (UC-MSCs) via peripheral vein injection preoperatively, and 5×10^6 cells via renal arterial injection during surgery, with standard induction therapy
Trial: 21518701
Drug: Leuprorelin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin therapy
Trial: 20035579
Drug: Risperidone 1-3
RxNorm normalized name: risperidone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1-3 mg/day
Trial: 21299844
Drug: Risperidone 4-6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4-6 mg/day
Trial: 15361496
Drug: Slow ramp
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow ramp rectal distension (40 ml/min)
Trial: 15361496
Drug: Rapid phasic
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid phasic rectal distension (900 ml/min, 10, 20, 30, and 40 mm Hg)
Trial: 9725691
Drug: Vancomycin administration
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin administration during surgery
Trial: 26067628
Drug: Ultrasound-guided pulsed
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided pulsed radiofrequency (PRF) treatment and night splint
Trial: 7582395
Drug: Inhaled B-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled B-agonist
Trial: 2350094
Drug: Codeine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (90 mg)
Trial: 31673875
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg/day orally on days 1-11, single oral dose of erdafitinib 4 mg on day 5
Trial: 31673875
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg/day orally on days 1-11, single oral dose of erdafitinib 4 mg on day 5
Trial: 31673875
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of erdafitinib 4 mg
Trial: 27437826
Drug: PC-1005 (MIV-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-1005 (MIV-150 and zinc acetate in a carrageenan gel)
Trial: 22418831
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg daily for 5 days)
Trial: 15968009
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month
Trial: 1283553
Drug: Deeper somatic
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deeper somatic pain descriptors (e.g., throbbing, stabbing, cramping, pulling, burning)
Trial: 1283553
Drug: Superficial pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial pain descriptors (e.g., pricking, sharp, pinching, itching, sore, tender)
Trial: 24117531
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg (single dose)
Trial: 24117531
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg (multiple doses)
Trial: 15958837
Drug: Indinavir/Ritonavir 800/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/Ritonavir 800/200 mg twice daily
Trial: 15958837
Drug: Indinavir/Ritonavir 400/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/Ritonavir 400/400 mg twice daily
Trial: 11796432
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI) 300 mg
Trial: 10232690
Drug: big ET‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: big ET‐1 infusion (0.2, 1, and 4 pmol/kg per min for 20 min)
Trial: 10232690
Drug: big ET‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: big ET‐1 infusion
Trial: 10232690
Drug: ET‐1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐1 infusion
Trial: 1297921
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (any treatment for hyperbilirubinemia)
Trial: 29389245
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g daily ARA for 4 weeks
Trial: 6124495
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative therapy
Trial: 19704275
Drug: Brace therapy
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace therapy for compression fractures
Trial: 19704275
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and postural instructions for compression fractures
Trial: 16926249
Drug: Pegvisomant (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (doses 10-60 mg)
Trial: 11385196
Drug: Fluoride group
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride group (mothers received fluoride varnish treatments at 6, 12, and 18 months after delivery)
Trial: 11385196
Drug: Chlorhexidine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine group (mothers received chlorhexidine varnish treatments at 6, 12, and 18 months after delivery)
Trial: 8506477
Drug: Ofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (400 mg twice daily for 10 days)
Trial: 8506477
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days)
Trial: 3899677
Drug: Vinpocetine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 40 mg
Trial: 27523947
Drug: Milbemycin oxime/praziquantel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milbemycin oxime/praziquantel tablets (G3)
Trial: 24871654
Drug: High-dose Ginseol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Ginseol K‐g1 (300 mg)
Trial: 24871654
Drug: Low-dose Ginseol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Ginseol K‐g1 (100 mg)
Trial: 21186645
Drug: Cycloferon liniment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloferon liniment in combined therapy
Trial: 18794178
Drug: Etanercept plus
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept plus sulfasalazine (2-3 g/day)
Trial: 15786440
Drug: Jet nebulizer
RxNorm normalized name: Pari LC Jet Nebulizer Plus RE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet nebulizer (0.15 mg/kg salbutamol respiratory solution)
Trial: 11976156
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet (4 servings/d of foods containing beta-glucan or psyllium delivering 8 g/d more soluble fiber)
Trial: 3261614
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (15 women)
Trial: 11318787
Drug: Acipimox (A)
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (A) 250 mg, orally, administered at -210 minutes and -60 minutes
Trial: 27379793
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (8 g kg(‐1))
Trial: 27379793
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (3 g kg(‐1))
Trial: 19713256
Drug: DEX (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (both doses)
Trial: 18631245
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg azithromycin once a day for 3 days
Trial: 12022709
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg o.d.
Trial: 30219823
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (LDMTX)
Trial: 3481039
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX)
Trial: 9454116
Drug: Crystallization test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystallization test with cupric chloride solution in patients with head and neck neoplasms
Trial: 343256
Drug: Cefazolin and
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin and cephalexin (prophylactic antibiotics)
Trial: 24756462
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of ibandronic acid (T)
Trial: 24756462
Drug: Bonviva(®) (R)
RxNorm normalized name: Boniva
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bonviva(®) (R) - first dosing
Trial: 24756462
Drug: Bonviva(®) (R)
RxNorm normalized name: Boniva
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bonviva(®) (R) - second dosing
Trial: 17625432
Drug: Amantadine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (200 mg/day, orally)
Trial: 9552780
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 mg/kg/h)
Trial: 3421279
Drug: Antenatal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal vitamin K1 (10 mg intramuscularly every 5 days until delivery)
Trial: 3421279
Drug: No antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antenatal vitamin K1 therapy
Trial: 25855751
Drug: Pay-for-reporting intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pay-for-reporting intervention with monthly incentive fees and chart audits every 6 months.
Trial: 16537663
Drug: Fondaparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5 mg daily)
Trial: 16537663
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg per kilogram of body weight twice daily)
Trial: 8129540
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg + Nifedipine 20 mg (AN)
Trial: 3524837
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) at total doses less than 902 mg/m2
Trial: 3524837
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) at total doses greater than 902 mg/m2
Trial: 3524837
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) at total doses exceeding 1400 mg/m2
Trial: 3524837
Drug: Misonidazole administration
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole administration
Trial: 22316106
Drug: Allopurinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (200 mg or 300 mg depending on renal function)
Trial: 20649528
Drug: High volume/low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume/low concentration solution of ropivacaine (20 ml, 0.5%)
Trial: 20649528
Drug: Low volume/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume/high concentration solution of ropivacaine (10 ml, 1%)
Trial: 20649528
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine injection
Trial: 15991756
Drug: Pharmacist-guided education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-guided education and monitoring (PGEM) through three monthly telephone calls
Trial: 1777051
Drug: Theophylline L.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline L.A.
Trial: 6362597
Drug: Immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune globulin (0.06 mL/kg of body weight)
Trial: 6362597
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immune globulin (0.06 mL/kg of body weight)
Trial: 6362597
Drug: Immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune globulin (twice the dose of the first group)
Trial: 28460586
Drug: [6S]-5-methyltetrahydrofolate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [6S]-5-methyltetrahydrofolate (400 μg/d)
Trial: 28460586
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 μg/d)
Trial: 28634649
Drug: Cabozantinib (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (140 mg/day)
Trial: 22849308
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg IV fluid administration
Trial: 22849308
Drug: 30 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL/kg IV fluid administration
Trial: 22849308
Drug: 2 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/kg IV fluid administration (control group)